MedTrace Logo

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.

NCT03076216 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2021-07-13

No results posted yet for this study

Summary

To evaluate the safety of OncoSil™ in a patient population undergoing standard chemotherapy treatment for pancreatic cancer. This study has been designed to satisfy FDA regulatory requirements.

The clinical investigation will be conducted at approximately 5 sites in the United States involving 20 patients.

Conditions

  • Unresectable Locally Advanced Pancreatic Carcinoma

Interventions

DEVICE

OncoSil™

The implantation of OncoSil™ under EUS

Sponsors & Collaborators

  • OncoSil Medical Limited

    lead INDUSTRY

Principal Investigators

  • Joseph M Herman, M.D., M.Sc. · MD Anderson Cancer Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-11-28
Completion
2020-11-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03076216 on ClinicalTrials.gov